

Figure 3: A scatter plot shows correlation between HDL and insulin in the study group($r = 0.06$, $p= 038$)




Figure 4: A scatter plot shows correlation between LDL and insulin in the study group($r = 0.06$, $p= 038$)

2. Materials and Methods

The present study is descriptive, analytic, cross-sectional and hospital-based study, it was carried out in educational hospitals of Khartoum State, Sudan. From March 2013 to May 2014, all patients selected had a history of PCOS. 200 patients diagnosed with PCOS were enrolled in this study. and 100 healthy women who had no history of drugs affecting lipid metabolism (with normal menstrual cycle and sex hormone level, no evidence of polycystic ovary) were selected as controls, written informed consent was obtained from all participants, all of them were age and weight-

matched, Blood was obtained to determine levels of serum insulin and lipid parameters. The blood samples were drawn after overnight fasting in the morning (between 0800 and 1100 h). Five ml of blood from each individual of study population were collected from both cases and control, the blood was centrifuged at 3000 rpm for 10 minutes and serum was obtained, samples were stored in +4 C until analyzed during the same day. ELISA techniques used for determine insulin level and enzymatic colorimetric methods used to determine total cholesterol, TGS, HDL-C and LDL-C Levels. All these parameters were investigated, recorded, and then a comparison was made between PCOS patients

and control participants. Later, the results were collected and presented in graphs and tables, showing the values as mean \pm standard deviation. Data were analyzed by computer program (SPSS) version IBM 20. Student T. test was used for the Calculation. $P \leq 0.05$ was considered significant. All chemical reagents were purchased from Bio system company (Spine Company for Analytical material and chemical Reagents).

3. Results

Total 200 patients with PCOS were included in the study, with a mean age of 29.61 ± 5.41 years. And 100 healthy women, with a mean age of 31.23 ± 4.93 years, and others basic characteristics of the study participates, body max index(BMI) of the PCOS patients is statistically significantly increased, compared with control group [Table 1]. Lipid profile parameters in PCOS group the (mean \pm SD) of serum insulin, triglyceride, total cholesterol, HDL and LDL were 11.06 ± 6.21 μ IU/ml, 89.89 ± 33.36 mg/dl, 166.95 ± 46.94 mg/dl, 43.83 ± 20.75 mg/dl and 104.55 ± 52.209 mg/dl, respectively while that of control group, the (mean \pm SD) of serum insulin, triglyceride, total cholesterol, HDL and LDL were 4.52 ± 1.60 μ IU/ml, 82.13 ± 26.51 mg/dl, 145.14 ± 31.019 mg/dl, 51.02 ± 14.81 mg/dl, and 72.62 ± 30.04 mg/dl, respectively [Table 2]. There was statistically significant increased levels of triglyceride, total cholesterol and LDL-C in PCOS group when compared to the control group ($P < 0.05$). With decreased level of HDL-C [Table 2]. In our study, there were colorations between serum insulin and lipid parameters in the study group.

[Figure 1] shows significant, strong positive correlation between insulin and the serum levels of triglycerides. ($r = 0.70$, $p = 0.2$).

[Figure 2] shows insignificant, very weak negative correlation between insulin and the serum levels of cholesterol. ($r = 0.02$, $p = 0.82$).

[Figure 3] shows significant, very weak positive correlation between insulin and the serum levels of high density lipoprotein. ($r = 0.27$, $p = 0.00$).

[Figure 4] shows significant, very weak negative correlation between insulin and the serum levels of low density lipoprotein. ($r = 0.11$, $p = 0.13$).

4. Discussion

The study was conducted to evaluate changes for lipids profile parameters in Sudanese polycystic ovarian syndrome (PCOS) patients and healthy women as control group. Polycystic ovarian syndrome is one of the important endocrine disorder causing reproductive abnormalities in women, which has heterogeneous clinical features and multifactorial in etiology [22]. Obesity and insulin resistance occur frequently in association with this syndrome. Cardiovascular risk factors seem to cluster in women with PCOS compared with general population [23]. Dyslipidemia is one of the important risk factor associated with PCOS. Abnormal lipid metabolism is one of the main metabolic characteristics of PCOS patients. The result of this study

showed that PCOS patients had higher TC, LDL-C, and TG and lower HDL-C when compared with age-matched healthy females [Table2] are similar to the results were observed in PCOS patients in another study [24] also in agreement with some studies suggest that PCOS patients are hyperlipidemic with higher total cholesterol, LDL-Cholesterol and triglycerides concentrations lower HDL-cholesterol levels than control [25]-[26]. On other hand, our results are disagree with the study done by Bickerton et. al [27]. Have demonstrated that there are no significant differences in lipid or lipoprotein concentrations between patients with PCOS and weight matched control. our present study demonstrated that serum insulin level significantly increased in patients with polycystic ovary syndrome when compared to the age- weight matched control group [Table 1], this agrees with a study done by Burghen et al [28] who reported association of (PCOS) with hyperinsulinemia. It has become clear that the syndrome has major metabolic as well as reproductive effects. Kierland et al [29] reported insulin-resistant diabetes mellitus in patients with (PCOS). These lipid abnormalities were closely related to insulin resistance independent of obesity [30]-[22]. The increase in triglycerides may be due the accumulation of triglycerides, which may occur due to the increased lipogenesis, due to decreased clearance or reduced oxidation of fatty acids. Increased secretion of VLDL particles by the liver results elevated plasma triglycerides concentration. This may occur due to insulin resistance, which is seen in PCOS patients. Insulin resistance also contributes more catabolism of HDL-C particles and formation of LDL-C [31]. Hyperandrogenism also contributes for alerted lipid profile, Hyperandrogenism has been associated with increased hepatic lipase activity has role in catabolism of HDL-C particles. Increased serum concentrations of triglycerides (TGs) have also been recognized as a risk factor for cardiovascular disease. [32] The present study showed significant, strong positive correlation between insulin and the serum triglycerides [Figure1]. This study shows that women with polycystic ovary syndrome had significantly decreased serum levels of HDL- cholesterol (HDL-C) compared with the control subjects our results in agreements with a study done in 1985, by Wild and colleagues [33]-[25] found that women with PCOS had lower HDL levels, higher LDL/HDL ratios, and higher triglyceride levels than regularly menstruating women. More recently, Slowinska-Szrednicka et al [34] have drawn attention to the role of insulin in the lipid abnormalities observed in hyperandrogenic women with PCOS. These investigators compared 27 women with PCOS and 22 eumenorrheic control subjects stratified by weight (obese and no obese). Women with PCOS had significantly lower levels of HDL₂ and higher levels of apoB and triglycerides.

This study demonstrates that women with polycystic ovary syndrome had higher significant increase in the serum levels of low density lipoprotein (LDL) as compared with the control subjects, these results agree with a study done by Imran et al [35].

The current study shows insignificant, correlation between insulin and the serum level of cholesterol [Figure 2]. this agrees with results of a study done by Imran et al [35] who concluded that women with polycystic ovary syndrome have

increased hepatic lipase activity and low density lipoprotein concentration relative to body mass index matched controls with normal menstrual rhythm and normal ovaries. Further, these metabolic disturbances appear related more closely to abnormal insulin metabolism and circulating androgen levels.

This study shows that women with polycystic ovary syndrome had significantly decreased serum levels of HDL-cholesterol (HDL-C) compared with the control subjects this result agrees with a study done by Wild et al [36] in 1985 who found that women with (PCOS) have lower serum levels of HDL-C in comparison with healthy control subjects. Recently, Slowinska -Srzednicka et al [34] have drawn attention to the role of insulin in the lipid abnormalities observed in hyperandrogenic women with PCOS. when compared 27 women with PCOS and 22 eumenorrheic control subjects stratified by weight (obese and non-obese), they found that women with PCOS had significantly lower levels of HDL. Also the study showed significant, very weak positive correlation between insulin and the serum levels of high density lipoprotein. [Figure 3]. In the present study women with polycystic ovary syndrome had significantly increased serum levels of total cholesterol compared with the control subjects. Our study, shows significant, very weak negative correlation between insulin and the serum level of low density lipoprotein. [Figure 4]

5. Conclusion

PCOS patients had significant increased levels of serum insulin and altered lipid profile, with higher levels of triglycerides, total cholesterol and LDL-C) and low serum level of HDL-C, there was hyperinsulinemia, which may be feature of insulin resistance (IR), and dyslipidemia which is associated with obesity and cardiovascular disease. Further studies are needed to clarify the role of insulin and lipids in these patients.

References

- [1] J. Adams, D. W. Polson, and S. Franks, "Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism," *British Medical Journal*, vol. 293, no. 6543, pp. 355–359, 1986.
- [2] Car BR, Williams's textbook of Endocrinology. 8th ed. Philadelphia.W.B Saunders Co, 1992; 733-798.
- [3] A. Galluzzo, M. C. Amato, and C. Giordano, "Insulin resistance and polycystic ovary syndrome," *Nutrition, Metabolism and Cardiovascular Diseases*, vol. 18, no. 7, pp. 511–518, 2008.
- [4] H. J. Teede, S. Hutchison, S. Zoungas, and C. Meyer, "Insulin resistance, the metabolic syndrome, diabetes, and cardiovascular disease risk in women with PCOS," *Endocrine*, vol. 30, no. 1, pp. 45–53, 2006.
- [5] Wild RA; Obesity, lipids, cardiovascular risk, and androgen excess. *Am J Med.*, 1995;98(suppl): 27S-32S
- [6] Aral SD, Cates WJr. The increasing consent with infertility: Why now. *J.A.M.A.* 1983; 250:2327-2331.
- [7] Morrell V. Basic fertility assessment. *Primary care women's Health*, 1998; 24:195-204.
- [8] Saxena P, Prakash A, Nigam A, Mishra A. Polycystic ovary syndrome: Is obesity a sine qua non? A clinical, hormonal, and metabolic assessment in relation to body mass index. *Indian J Endocrinol Metab* 2012; 16:996-9.
- [9] Mohamadin AM, Habib FA, Al-Saggal AA. Cardiovascular disease markers in women with polycystic ovary syndrome with emphasis on asymmetric dimethylarginine and homocysteine. *Ann Saudi Med* 2010;30:278-83.
- [10] Gonzalez F, Rote NS, Minium J, Kirwan JP. Evidence of proatherogenic inflammation in polycystic ovary syndrome. *Metabolism* 2009;58:954-62.
- [11] Pepe I, Agrusa A, Rinella MR, Fertita E, Gulatta P, Scozzari F, et al. Heterogenous forms of dyslipidemia in women with polycystic ovary syndrome. *Acta Medica Mediterranea* 2008;24;133-9.
- [12] Lergo RS, Kunselman AR, Dunaif A; Prevalence and predictors of dyslipidaemia in women with polycystic ovary syndrome, *Am J Med.*, 2001; 111: 607-613.
- [13] Dahlgren EI, Johansson S, Lindstedt G, Knutsson F, Odén A, Janson PO *et al.*; Women with polycystic ovary wedge resected in 1956 to 1965; a long - term follow-up focusing on natural history and circulating hormones. *Fertil Steril.*, 1992; 57: 505-513.
- [14] Talbott E, Clerici A, Berga SL, Kuller L, Guzick D, Detre K *et al.*; Adverse lipid and coronary heart disease risk profiles in young women with polycystic ovary syndrome, results of a case -control study. *J Clin Epidemiol.*, 1998; 51: 415-422.
- [15] Conway GS1, Agrawal R, Betteridge DJ, Jacobs HS; Risk factors for coronary artery diseases in lean and obese women with polycystic ovary syndrome. *Clin Endocrinol. (Oxf)*, 1992; 37(2): 119-125.
- [16] Wild RA, Painter PC, Coulson PB, Carruth KB, Ranney GB. Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome. *J Clin Endocrinol Metab.* 1985;61(5):946-951.
- [17] Talbott E, Guzick D, Clerici A, Berga S, Detre K, Weimer K, Kuller L, coronary heart disease risk factors in women with polycystic ovary syndrome, *Arterioscler Thromb Vas Biol* 1995 15(7):821-826.
- [18] Conway GS, Agrawal R, Betteridge DJ, Jacobs HS; Risk factors for coronary artery diseases in lean and obese women with polycystic ovary syndrome. *Clin Endocrinol. (Oxf)*, 1992; 37(2): 119-125.
- [19] Pirwany IR, Fleming R, Greer IA, Packard CJ, Sattar N. Lipid and Lipoprotein subfraction in women with PCOS: relationship to metabolic and endocrine parameters. *Clin Endocrinol. (Oxf)*, 2001; 54(4): 447-453.
- [20] Graf MJ, Richards CJ, Brown V, Meissner L, Dunaif A. The independent effects of hyperandrogenaemia, hyperinsulinaemia, and obesity on lipid and lipoprotein profile in women. *Clin Endocrinol. (Oxf)*, 1990; 33(1): 119-131.
- [21] Holte J, Bergh T, Berne C, Lithell H. Serum lipoprotein lipid profile in women with Polycystic ovary syndrome: relation to anthropometric, endocrine and metabolic variables. *Clin Endocrinol. (Oxf)*, 1994; 41(4): 463-471.

- [22] Zawadic JK, Danif A; Diagnostic criteria for polycystic ovarian syndrome towards a rational approach, polycystic ovaria syndrome. Cambridge, England: Blackwell science, 1992:377-384.
- [23] Wlidi RA; long term health consequences of PCOS. Hum Reprod Updated, 2002;8(3):231-241.
- [24] Valkenburg O, Steegers-Theunissen RP, Smedts HP, Dallinga-Thie GM, Fauser BC, Westerveld EH, et al. A more atherogenic serum lipoprotein profile is present in women with polycystic ovary syndrome: A case-control study. J Clin Endocrinol Metab 2008;93:470-6.
- [25] Meiro WD, Razl, Yoss Cpouitch O, Brzezinski A, Rosler A, Schenker JG, Berry EM, Dyslipidaemia in polycystic ovarian syndrome: different group, different aetiologies? Hum Reprod 1996; 11(9):1848-1853.
- [26] Orio Fjr, Palombas, Spinelil et al. The cardiovascular risk in women with polycystic ovary syndrome an observational, analytical prospective case-control study J Clin Endocrine Metab 2004;89(8):3696-3701.
- [27] Bickerton AS, Clark N, Meeking D et al. Cardiovascular risk in women with polycystic ovarian syndrome (PCOS). J Clin Pathol 2005; 58(2):151-154.
- [28] Burghen GA, Givens JR, Kitabchi AE. Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease. J Clin Endocrinol Metab 1980; 50:113-118.
- [29] Kierland RR. Acanthosis nigricans: An analysis of data in twenty-two cases and a study of its frequency in necropsy material. J Invest Dermatol 1974;9: 299-305.
- [30] S. Tangvarasittichai, P. Poosub, and O. Tangvarasittichai, "Association of serum lipoprotein ratios with insulin resistance in type 2 diabetes mellitus," Indian Journal of Medical Research, vol. 131, no. 5, pp. 641-648, 2010.
- [31] P. Saxena, A. Prakash, and A. Nigam, "Efficacy of 2-hour post glucose insulin levels in predicting insulin resistance in polycystic ovarian syndrome with infertility," Journal of Human Reproductive Sciences, vol. 4, no. 1, pp. 20-22, 2011.
- [32] St-Onge MP, Janssen I and Heymsfield SB (2004); Metabolic syndrome in normal-weight Americans: new definition of the metabolically obese, normal-weight individual. Diabetes Care 27, 2222-2228.
- [33] Wild R, Painter P, Coulson P, Carruth K, Ranney G. Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1985;61:946-951.
- [34] Slowinska-Srzednicka J, Zgliczynski S, Wierzbicki M, Srzednicki M, Stopinska-Gluszak U, Zgliczynski W, Soszynski P, Chotkowska E, Bednarska M, Sadowaki Z. The role of hyperinsulinemia in the development of lipid disturbances in non-obese and obese women with the polycystic ovary syndrome. J Endocrinol Invest. 1991; 14:569-575.
- [35] Imran Pirwany, Obstetrics and Gynecology, 2009; 310-312.
- [36] Wild R, Painter P, Coulson P, Carruth K, Ranney G. Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1985; 61:946-951.